title: PTCL therapies: a review of treatment and outline of novel therapies.
abstract: Peripheral T-cell lymphomas (PTCLs) are relatively uncommon lymphomas, compared with B-cell malignancies, and given short-lived responses to therapies and an aggressive clinical course provide a therapeutic challenge for the clinician. Although anthracycline-based regimens have been a mainstay of therapy, inferior outcomes with these regimens have called attention to the need for the development of novel agents and effective combination therapies. Recently, new agents with activity in PTCL have emerged with evidence of improved efficacy. This review summarizes novel, investigational, and standard treatment options in the management of treatment naive and relapsed refractory PTCL.
authors.affiliation: Department of Hematology-Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington DC.
authors.forename: Nadia
authors.initials: N
authors.lastname: Khan
authors.forename: Bruce D
authors.initials: BD
authors.lastname: Cheson
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D056747:Immunomodulation; D016411:Lymphoma, T-Cell, Peripheral / Q000188:drug therapy* / Q000401:mortality; D011379:Prognosis
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents